Evaluation of Clay/poly (L – Lactide) microcomposites as anticancer drug, 6 – Mercaptopurine reservoir through in vitro cytotoxicity, oxidative stress markers and in vivo pharmacokinetics

Abstract

tIntercalation of 6-mercaptopurine (6-MP), an antineoplastic drug in interlayer gallery of Na+-clay (MMT)was further entrapped in poly (l-lactide) matrix to form microcomposite spheres (MPs) in order to reducethe cell toxicity and enhance in vitro release and pharmacokinetic proficiency. The drug–clay hybridwas fabricated via intercalation by ion-exchange method to form MPs from hybrid. In vitro drug releaseshowed controlled pattern, fitted to kinetic models suggested controlled exchange and partial diffusionthrough swollen matrix of clay inter layered gallery. The in vitro efficacy of formulated composites drugwas tested in Human neuroblastoma cell line (IMR32) by various cell cytotoxic and oxidative stressmarker indices. In vivo pharmacokinetics suggested that the intensity of formulated drug level in plasmawas within remedial borders as compared to free drug. These clay based composites therefore have greatpotential of becoming a new dosage form of 6-MP.